title: TLK-286.
abstract: Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.
authors.affiliation: University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA. cverschraegen@salud.unm.edu
authors.forename: Claire F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: Harriet O
authors.initials: HO
authors.lastname: Smith
authors.forename: Fa Chyi
authors.initials: FC
authors.lastname: Lee
authors.forename: Cynthia
authors.initials: C
authors.lastname: Cathcart
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Norenberg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005978:Glutathione / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; C107479:TER 286; D005978:Glutathione